Technologies
PDF


WARF: P150198US02

Effective and Robust Method of T Cell Expansion and Activation


INVENTORS -

Peiman Hematti, Debra Bloom

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for efficiently expanding and activating T cell populations for genetic engineering and adoptive T cell immunotherapies.

The new method is based in part on the researchers' discovery of the role of BAFF (B cell activating factor) and its receptor BAFF-R/BR3 in T cell suppression, and removes a significant bottleneck in the production/manufacture of T cells.
OVERVIEWT cell based immunotherapy is a rapidly growing field that has experienced impressive clinical anti-cancer successes in the last few years. In particular, it is now possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. Ex vivo expansion and activation of T cells are prerequisites for any form of genetically engineered T cell immunotherapy.

Several expansion and activation methodologies have been developed. However, widespread utilization of T cell immunotherapies for treatment of malignancies and potentially many other diseases has been hindered by the lack of rapid, cost-effective and efficient methods for selecting and expanding clinical-grade, therapeutic T cell products that proliferate and persist in vivo.

There remains a need for more robust methodologies for expanding T cell populations having clinical therapeutic potential.
THE INVENTIONUW–Madison researchers have shown for the first time that the addition of inhibitors which block the binding of BAFF to its receptor BAFF-R/BR3 activates both CD4+ and CD8+ cytolytic T cells such that the killing of target human tumor cell lines is significantly augmented.

Specifically, the researchers demonstrated in vitro that a neutralization antibody to the BAFF receptor, BR3, significantly increased CRTAM+ CD4+ and CD8+ T cell proliferation and their anti-tumor cytotoxic activity via increases in granzyme B. This was shown for even aggressive melanoma cell lines such as A375 whereby a four day co-culture with BR3 neutralized T cells almost completely eradicated the tumor cells from culture. This innovation removes a significant roadblock in the industrial production/manufacture of T cells ex vivo for T cell and chimeric antigen receptor (CAR) T cell immunotherapy, which is currently one of the most exciting new cancer therapies.
APPLICATIONS
  • Expansion and activation of T cell populations for genetic engineering and adoptive T cell immunotherapies
KEY BENEFITS
  • Potential for effective, efficient and robust results
  • Based on a novel UW–Madison discovery
  • Promising early stage data
STAGE OF DEVELOPMENTIn vitro data support the researchers’ hypothesis that BAFF, when bound to its receptor BR3, mediates T cell suppression. When peripheral blood lymphocytes are stimulated with T cell stimulatory antibodies anti-CD3 and anti-CD28, both CD4+ and CD8+ T cell proliferation is induced. Addition of antibodies that specifically neutralize the BAFF receptor BR3 further expands proliferation of both cytotoxic CD4+ and CD8+ T cells significantly.

The researchers also detected extreme increases in IFN-γ production as well as increases in the production and/or secretion of the CD8+ T cell toxin granzyme B. These data strongly suggest that BR3 is one of the essential suppressors of CD4+ and CD8+ cytotoxic T cell activation and proliferation. These new data demonstrate that BAFF blockade can actively and significantly increase a T cell-mediated immune response.

The development of this technology was supported by WARF Accelerator. WARF Accelerator selects WARF's most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones. WARF believes that these technologies are especially attractive opportunities for licensing.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.